

January 6, 2016



## BioSig Technologies to Present at 8th Annual Biotech Showcase

Minneapolis, MN, Jan. 06, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) today announced that it will be presenting at the 8th Annual Biotech Showcase(TM) to be held January 11-13, 2016 in San Francisco, California.

**Event:** Biotech Showcase 2016

**Location:** Parc 55 Hilton Hotel, San Francisco

**Date:** Tuesday January 12, 2016

**Time:** 11:30 AM (PST)

BioSig Executive Chairman, Ken Londoner will deliver the Company's corporate presentation and discuss recent business highlights. To arrange a meeting with management, please contact Robert Haag at [bsgm@irthcommunications.com](mailto:bsgm@irthcommunications.com) or 1-866-976-4784.

### About BioSig Technologies

BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the \$3 billion electrophysiology (EP) marketplace(1) ([www.biosigtech.com](http://www.biosigtech.com)). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.

PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from \$2.5 billion in 2012 to \$5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).

BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical

studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.

1. Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
2. HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; \*AF includes left atrial tachycardia, left WPW, left atrial flutter.

Contact:

Investor Relations:

Brian McLaughlin

BioSig Technologies, Inc.

bmclaughlin@biosigtech.com

917-370-9817

Robert Haag

Managing Partner

IRTH Communications

BSGM@irthcommunications.com

866-976-4784



Source: BioSig Technologies, Inc.